Featured Research

from universities, journals, and other organizations

Octreotide acetate does not prevent treatment-induced diarrhea in anorectal cancer

Date:
March 24, 2010
Source:
Journal of the National Cancer Institute
Summary:
In many cancers, octreotide acetate has been reported to control the diarrhea that can accompany chemotherapy. However, for patients receiving combined chemotherapy and radiation for anal or rectal cancers, the drug proved no better than a placebo in a randomized trial.

In many cancers, octreotide acetate (Sandostatin) has been reported to control the diarrhea that can accompany chemotherapy. However, for patients receiving combined chemotherapy and radiation for anal or rectal cancers, the drug proved no better than a placebo in a randomized trial that was published online March 24 in the Journal of the National Cancer Institute.

Related Articles


Chemotherapy and radiation, given concurrently, are standard treatments for anorectal cancers, which are diagnosed in about 46,000 people in the United States each year. The side effects of the combined therapy can include acute diarrhea, often so severe that patients must delay or discontinue treatment or be treated with lower doses, compromising the chances of cure.

To see whether octreotide acetate could reduce diarrhea in anorectal cancer patients, Babu Zachariah, M.D., Clement Gwede, Ph.D. and colleagues in the Radiation Therapy Oncology Group conducted a randomized, controlled, double-blinded trial. Patients were assigned to receive either a 30mg dose of long-acting octreotide or a placebo between 4 and 7 days before the start of radiation therapy and again about three weeks later. A total of 215 patients were included in the final analysis.

The rates of acute diarrhea were similar in the two groups. The researchers found no statistically significant differences in the number of patients who had to modify their treatment doses or schedules. There were likewise no differences between the groups in rates of hospitalization, usage of other medical resources, or quality of life.

"In this study," the authors conclude, "the prophylactic use of [long-acting octreotide acetate] did not prevent the incidence or reduce the severity of diarrhea and had no notable impact on patient-reported bowel function or quality of life."

Study Limitations: The study did not account for the surgical status (pre- vs postoperative) of the patients and the bowel sparing techniques that can reduce the incidence of diarrhea.


Story Source:

The above story is based on materials provided by Journal of the National Cancer Institute. Note: Materials may be edited for content and length.


Cite This Page:

Journal of the National Cancer Institute. "Octreotide acetate does not prevent treatment-induced diarrhea in anorectal cancer." ScienceDaily. ScienceDaily, 24 March 2010. <www.sciencedaily.com/releases/2010/03/100324162617.htm>.
Journal of the National Cancer Institute. (2010, March 24). Octreotide acetate does not prevent treatment-induced diarrhea in anorectal cancer. ScienceDaily. Retrieved October 24, 2014 from www.sciencedaily.com/releases/2010/03/100324162617.htm
Journal of the National Cancer Institute. "Octreotide acetate does not prevent treatment-induced diarrhea in anorectal cancer." ScienceDaily. www.sciencedaily.com/releases/2010/03/100324162617.htm (accessed October 24, 2014).

Share This



More Health & Medicine News

Friday, October 24, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

IKEA Desk Converts From Standing to Sitting With One Button

IKEA Desk Converts From Standing to Sitting With One Button

Buzz60 (Oct. 24, 2014) IKEA is out with a new convertible desk that can convert from a sitting desk to a standing one with just the push of a button. Jen Markham explains. Video provided by Buzz60
Powered by NewsLook.com
Ebola Protective Suits Being Made in China

Ebola Protective Suits Being Made in China

AFP (Oct. 24, 2014) A factory in China is busy making Ebola protective suits for healthcare workers and others fighting the spread of the virus. Duration: 00:38 Video provided by AFP
Powered by NewsLook.com
WHO: Millions of Ebola Vaccine Doses by 2015

WHO: Millions of Ebola Vaccine Doses by 2015

AP (Oct. 24, 2014) The World Health Organization said on Friday that millions of doses of two experimental Ebola vaccines could be ready for use in 2015 and five more experimental vaccines would start being tested in March. (Oct. 24) Video provided by AP
Powered by NewsLook.com
Doctor in NYC Quarantined With Ebola

Doctor in NYC Quarantined With Ebola

AP (Oct. 24, 2014) An emergency room doctor who recently returned to the city after treating Ebola patients in West Africa has tested positive for the virus. He's quarantined in a hospital. (Oct. 24) Video provided by AP
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:

Strange & Offbeat Stories


Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins